The U.S. Food and Drug Administration (FDA) has approved LIB Therapeutics’ LEROCHOL (lerodalcibep-liga) for the treatment of adults with elevated low-density lipoprotein cholesterol (LDL-C)—marking a significant advancement in cardiovascular disease management and representing an important addition to the therapeutic options for patients who struggle to meet LDL-C targets with existing treatments.

LEROCHOL, a novel, third-generation PCSK9 inhibitor developed by LIB Therapeutics, is designed to provide robust and sustained reductions in LDL-C through a convenient, once-monthly subcutaneous administration. The approval reflects positive outcomes from the comprehensive Phase 3 LIBerate clinical program, which demonstrated meaningful lowering of LDL-C in a broad patient population, including those with heterozygous familial hypercholesterolemia and other high-risk groups.

Astrea Bioseparations, which supports the biopharmaceutical industry through the supply of critical materials, was part of the supply chain for LEROCHOL.